WO2008112317A2 - Triol form of rosuvastatin - Google Patents
Triol form of rosuvastatin Download PDFInfo
- Publication number
- WO2008112317A2 WO2008112317A2 PCT/US2008/003470 US2008003470W WO2008112317A2 WO 2008112317 A2 WO2008112317 A2 WO 2008112317A2 US 2008003470 W US2008003470 W US 2008003470W WO 2008112317 A2 WO2008112317 A2 WO 2008112317A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rosuvastatin
- triol
- ester
- calcium
- diol
- Prior art date
Links
- 0 CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c(cc2)ccc2F)c1C(C[C@](C[C@](CC(O*)=O)O)O)O Chemical compound CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c(cc2)ccc2F)c1C(C[C@](C[C@](CC(O*)=O)O)O)O 0.000 description 3
- DNOJAPTZIBQJLV-RTKIROINSA-N CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c(cc2)ccc2F)c1C(C[C@H](C[C@H](CC(O)=O)O)O)O Chemical compound CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c(cc2)ccc2F)c1C(C[C@H](C[C@H](CC(O)=O)O)O)O DNOJAPTZIBQJLV-RTKIROINSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to rosuvastatin triol and its use as a reference standard for analysis of rosuvastatin.
- Statins are currently the most therapeutically effective drugs available for reducing low-density lipoprotein (LDL) particle concentration in the blood stream of patients at risk for cardiovascular disease.
- LDL low-density lipoprotein
- statins are used in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.
- a high level of LDL in the bloodstream has been linked to the formation of coronary lesions that obstruct the flow of blood and can rupture and promote thrombosis.
- Goodman and Gilman The Pharmacological Basis of Therapeutics, page 879 (9th Ed. 1996).
- HMG-CoA reductase catalyzes the conversion of HMG to mevalonate, which is the rate-determining step in the biosynthesis of cholesterol. Decreased production of cholesterol causes an increase in the number of LDL receptors and corresponding reduction in the concentration of LDL particles in the bloodstream. Reduction in the LDL level in the bloodstream reduces the risk of coronary artery disease. J.A.M.A., 1984, 251, 351-74.
- statins include lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin and atorvastatin.
- Lovastatin (disclosed in U.S. Pat. No. 4,231,938) and simvastatin (disclosed in U.S. Pat. No. 4,444,784) are administered in the lactone form. After absorption, the lactone ring is opened in the liver by chemical or enzymatic hydrolysis, and the active hydroxy acid is generated.
- Pravastatin (disclosed in U.S. Pat. No. 4,346,227) is administered as the sodium salt.
- Fluvastatin (disclosed in U.S. Pat. No.
- cerivastatin (disclosed in U.S. Pat. Nos. 5,006,530 and 5,177,080), also administered as the sodium salt, are entirely synthetic compounds that are in part structurally distinct from the fungal derivatives of this class that contain a hexahydronaphthalene ring. Atorvastatin and two new “superstates,” rosuvastatin and pitavastatin, are administered as calcium salts.
- Rosuvastatin calcium (monocalcium bis (+) 7-[4-(4-fluorophenyl)-6- isopropyl-2-(N-methyl-N-methylsulfonylaminopyrimidin)-5-yl]-(3R,5S)-dihydroxy- (E)- ⁇ -heptenoate) is an HMG-CoA reductase inhibitor, developed by Shionogi for the once daily oral treatment of hyperlipidaemia (Ann Rep, Shionogi, 1996; Direct communications, Shionogi, 8 Feb 1999 & 25 Feb 2000). Rosuvastatin calcium has the following chemical formula:
- Rosuvastatin calcium is marketed under the name CRESTOR for treatment of a mammal such as a human. According to the maker of CRESTOR ® , it is administered in a daily dose of from about 5 mg to about 40 mg. For patients requiring less aggressive LDL-C reductions or who have pre-disposing factors for myopathy, the 5 mg dose is recommended, while 10 mg dose is recommended for the average patient, 20 mg dose for patients with marked hypercholesterolemia and aggressive lipid targets (>190 mg/dL), and the 40 mg dose for patients who have not been responsive to lower doses.
- CRESTOR ® Rosuvastatin calcium is marketed under the name CRESTOR for treatment of a mammal such as a human. According to the maker of CRESTOR ® , it is administered in a daily dose of from about 5 mg to about 40 mg. For patients requiring less aggressive LDL-C reductions or who have pre-disposing factors for myopathy, the 5 mg dose is recommended, while 10 mg dose is recommended for the average patient
- U.S. Pat. No. 5,260,440 discloses and claims rosuvastatin, its calcium salt (2:1), and its lactone form.
- the process of the '440 patent prepares rosuvastatin by reacting 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5- pyrimidinecarbaldehyde with methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6- triphenylphosphoranylidene hexanate in acetonitrile under reflux.
- the silyl group is then cleaved with hydrogen fluoride, followed by reduction with sodium borohydride (NaBH 4 ) and diethylmethoxyborane in tetrahydrofuran (THF) to obtain a methyl ester of rosuvastatin.
- NaBH 4 sodium borohydride
- THF tetrahydrofuran
- the ester is then hydrolyzed with sodium hydroxide (NaOH) in ethanol at room temperature, followed by removal of ethanol and addition of ether, to obtain the sodium salt of rosuvastatin.
- NaOH sodium hydroxide
- the sodium salt is then converted to the calcium salt.
- the sodium salt is dissolved in water and maintained under a nitrogen atmosphere.
- Calcium chloride is then added to the solution, resulting in precipitation of rosuvastatin calcium (2:1).
- the product mixture of a reaction rarely is a single compound pure enough to comply with pharmaceutical standards. Side products and byproducts of the reaction and adjunct reagents used in the reaction will, in most cases, be present.
- the rosuvastatin must be analyzed for purity, typically by HPLC or GC analysis, to determine if it is suitable for continued processing or ultimately for use in a pharmaceutical product.
- the rosuvastatin does not need to be absolutely pure. Absolute purity is a theoretical ideal that is unattainable. Rather, there are purity standards intended to ensure that an API is not made less safe for clinical use because of the presence of impurities. In the United States, the Food and Drug Administration guidelines recommend that applicants limit some impurities to below 0.1%.
- impurities side products, byproducts and adjunct reagents (collectively “impurities”) are identified spectroscopically and by other physical methods and then the impurities are associated with a peak position in a chromatogram (or a spot on a TLC plate).
- impurities are associated with a peak position in a chromatogram (or a spot on a TLC plate).
- the impurity can be identified by its position in the chromatogram, which is conventionally measured in minutes between injection of the sample on the column and elution of the particular component through the detector, known as the "retention time.” This time period varies daily based upon the condition of the instrumentation and many other factors. To mitigate the effect that such variations have upon accurate identification of an impurity, practitioners use "relative retention time" ("RRT”) to identify impurities. (Strobel p. 922). The RRT of an impurity is its retention time divided by the retention time of some reference marker.
- rosuvastatin itself could be used as the reference marker, but as a practical matter it is present in such overwhelming proportion in the mixture that it tends to saturate the column, leading to irreproducible retention times, i.e., the maximum of the peak corresponding to rosuvastatin tends to wander (Strobel Fig. 24.8(b) p. 879, contains an illustration of the sort of asymmetric peak that is observed when a column is overloaded).
- a compound in a relatively pure state can be used as a "reference standard" (a "reference marker” is similar to a reference standard but it is used for qualitative analysis) to quantify the amount of the compound in an unknown mixture.
- a reference standard a solution of a known concentration of the compound is analyzed by the same technique as the unknown mixture. (Strobel p. 924, Snyder p. 549) (Snyder, L.R.; Kirkland, JJ. Introduction to Modern Liquid Chromatography, 2nd ed. (John Wiley & Sons: New York 1979)).
- the amount of the compound in the mixture can be determined by comparing the magnitude of the detector response. See also USP 6,333,198, incorporated herein by reference.
- the reference standard compound also can be used to quantify the amount of another compound in the mixture if the "response factor," which compensates for differences in the sensitivity of the detector to the two compounds, has been predetermined. (Strobel p. 894).
- the reference standard compound may be added directly to the mixture, in which case it is called an "internal standard.” (Strobel p. 925, Snyder p. 552).
- the reference standard compound can even be used as an internal standard when the unknown mixture contains some of the reference standard compound by using a technique called "standard addition," wherein at least two samples are prepared by adding known and differing amounts of the internal standard. (Strobel pp. 391-393, Snyder pp. 571, 572).
- the proportion of detector response due to the reference standard compound that is originally in the mixture can be determined by extrapolation of a plot of detector response versus the amount of the reference standard compound that was added to each of the samples to zero. (e.g. Strobel, Fig. 11.4 p. 392).
- the present invention provides compounds that can be used as a reference standard and reference marker for quantification and identification of rosuvastatin and impurities present in batches of rosuvastatin.
- the present invention provides a rosuvastatin triol having the following structure:
- X is a hydrogen, a C 1 -C 4 alkyl group, or an alkali or alkaline earth metal cation, with the proviso that when X is an alkaline earth metal, two molecules of rosuvastatin are present to one of the metal cation.
- the present invention provides a rosuvastatin triol in acid form has the following structure:
- the present invention provides a rosuvastatin triol in ester form having the following structure:
- R is a C 1 -C 4 alkyl ester.
- the present invention provides a rosuvastatin triol in salt form having the following structure:
- M is an alkali or alkaline earth metal cation, with the proviso that when X is an alkaline earth metal, two molecules of rosuvastatin are present to one of the metal cation.
- the present invention provides a rosuvastatin triol in lactone form having the following structure:
- the present invention provides each of the above forms of the triol in isolated or purified form, substantially free of the corresponding rosuvastatin diol form.
- the present invention provides a process for preparing a rosuvastatin triol Ci-C 4 ester comprising combining rosuvastatin C 1 -C 4 ester with a solution of borane dimethylsulfide complex in a suitable organic solvent to obtain a reaction mixture, combining the resulting reaction mixture with a solution of NaOH in water, adding hydrogen peroxide (H 2 O 2 ) and recovering the triol ester.
- the present invention provides a process for preparing rosuvastatin triol Ci-C 4 ester comprising oxidizing rosuvastatin diol Ci to C 4 ester to obtain the rosuvastatin triol ester with a hydroxyl group at position 7.
- the present invention provides a process comprising combining rosuvastatin C 1 -C 4 ester with a solution of a borane in an organic solvent to obtain a reaction mixture, combining the resulting reaction mixture with a solution of an inorganic base in water, and adding peroxide and recovering the triol ester.
- the present invention provides a process for reducing amount of impurities present in rosuvastatin calcium by measuring amount of rosuvastatin calcium triol in batches of rosuvastatin calcium, selecting batches of the rosuvastatin calcium with desirable level of the triol and preparing pharmaceutical compositions with the selected rosuvastatin calcium batch.
- the present invention provides a process for reducing amount of rosuvastatin triol calcium present in a mixture comprising rosuvastatin diol calcium and rosuvastatin triol calcium comprising measuring amount of rosuvastatin triol C 1 -C 4 ester in batches of rosuvastatin diol Ci-C 4 ester, selecting batches of the rosuvastatin diol CpC 4 ester with of the triol Ci-C 4 ester and preparing pharmaceutical compositions of rosuvastatin diol calcium with the selected rosuvastatin diol Ci-C 4 ester batch.
- the present invention provides a method of determining the amount of an impurity in a sample of rosuvastatin ester (preferable t- butyl) comprising measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol ester in a reference standard comprising a known amount of rosuvastatin triol ester (preferably t-butyl); measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol ester in a sample comprising rosuvastatin triol and rosuvastatin diol esters (preferably t-butyl); and determining the amount of the rosuvastatin triol ester in the sample by comparing the area of reference standard with that of the test sample.
- the present invention provides a method of determining the amount of an impurity in a sample of rosuvastatin calcium comprising measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol calcium in a reference standard comprising a known amount of rosuvastatin triol calcium; measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol calcium in a sample comprising rosuvastatin triol and rosuvastatin diol calcium salts; and determining the amount of the triol calcium in the sample by comparing the area of reference standard with that of the test sample.
- the present invention provides a method of identifying the relative retention time (RRT) of an impurity in a sample of rosuvastatin diol ester (preferably t-butyl) comprising measuring by GC or HPLC the relative retention time (RRT) corresponding to rosuvastatin triol ester in a reference marker sample; carrying out GC or HPLC with a test sample comprising of the rosuvastatin diol ester and rosuvastatin triol ester to obtain an GC or HPLC chromatogram with retention times; and determining the relative retention time (RRT) of the triol ester in the sample by comparing the relative retention time (RRT) of the reference marker to the relative retention time (RRT) of the test sample.
- RRT relative retention time
- the present invention provides a method of identifying the relative retention time (RRT) of an impurity in a sample of rosuvastatin diol calcium comprising measuring by GC or HPLC the relative retention time (RRT) corresponding to rosuvastatin triol calcium in a reference marker sample; carrying out GC or HPLC with a test sample comprising of the rosuvastatin diol and rosuvastatin triol calcium salts to obtain an GC or HPLC chromatogram with retention times; and determining the relative retention time (RRT) of the triol calcium in the sample by comparing the relative retention time (RRT) of the reference marker to the relative retention time (RRT) of the test sample.
- the present invention provides a process for preparing rosuvastatin triol acid with the following structure: comprising hydrolyzing an ester of the following strcutre
- the present invention provides a process for preparing rosuvastatin triol lactone with the following structure:
- the present invention provides a process for preparing rosuvastatin triol acid with the following structure:
- M is an alkali metal or an alkaline earth metal with the proviso that if the metal cation is an alkaline earth metal, two molecules of rosuvastatin are present for each cation. .
- Figure 1 is an NMR of TBRE (t-butyl Rosuvastatin Ester) triol.
- Figure 2 is an HPLC chromatogram illustrating use of rosuvastatin triol calcium as a reference standard (including a reference marker).
- diol refers to the two hydroxyl groups present on rosuvastatin. Diol rosuvastatin is used herein synonymously as rosuvastatin.
- substantially free refers to having less than about 30% of the corresponding compound (e.g., diol or diastereoisomer), more preferably less than about 20%, even more preferably less than about 10%, and most preferably less than about 5%, based on area percentage HPLC.
- triol lactone refers to the lactone of rosuvastatin triol.
- the term "reference standard” refers to a compound that may be used both for quantitative and qualitative analysis of an active pharmaceutical ingredient.
- the retention time of the compound in HPLC allows for setting a relative retention time, thus making qualitative analysis possible.
- the concentration of the compound in solution before injection into an HPLC column allows for comparison of the areas under the peaks in an HPLC chromatogram, thus making quantitative analysis possible.
- a “reference marker” is used in qualitative analysis to identify components of a mixture based upon their position, e.g. in a chromatogram or on a Thin Layer Chromatography (TLC) plate (Strobel pp. 921, 922, 953). For this purpose, the compound does not necessarily have to be added to the mixture if it is present in the mixture.
- a “reference marker” is used only for qualitative analysis, while a reference standard may be used for quantitative or qualitative analysis, or both. Hence, a reference marker is a subset of a reference standard, and is included within the definition of a reference standard.
- the detector response can be, for example, the peak heights or integrated peak areas of a chromatogram obtained, e.g. by UV or refractive index detection, from the eluent of an HPLC system or, e.g. flame ionization detection or thermal conductivity detection, from the eluent of a gas chromatograph, or other detector response, e.g. the UV absorbance, of spots on a fluorescent TLC plate.
- the position of the reference standard may be used to calculate the relative retention time for rosuvastatin and other impurities.
- the present invention provides a rosuvastatin triol having the following structure:
- X is a hydrogen, an alkali or alkaline earth metal or a C 1 -C 4 alkyl group.
- X is hydrogen (i.e. rosuvastatin triol acid), calcium (Ca 2+ ) (i.e. rosuvastatin triol calcium) or tert-butyl (i.e. rosuvastatin triol tert-butyl ester ("TBRE")).
- TBRE rosuvastatin triol having the following structure: wherein X is a hydrogen, an alkali or alkaline earth metal or a C 1 -C 4 alkyl group.
- X is hydrogen (i.e.
- rosuvastatin triol acid i.e. rosuvastatin triol calcium
- tert-butyl i.e. rosuvastatin triol tert-butyl ester
- the present invention provides a rosuvastatin triol in an acid form having the following structure:
- the present invention provides rosuvastatin triol in ester form having the following structure
- R is a Ci-C 4 alkyl group.
- R is a t-butyl or methyl group. More preferably, the R is t-butyl.
- the present invention provides rosuvastatin triol in a salt form having the following structure:
- M is an alkali metal or alkaline earth metal cation.
- M is calcium.
- the salt would be a hemi calcium salt (2:1 ratio):
- the present invention further provides rosuvastatin triol in lactone form has the following structure:
- the present invention also provides each of the above forms of the rosuvastatin triol substantially free of the corresponding rosuvastatin diol form.
- the present invention provides: a) Rosuvastatin triol Ci-C 4 ester substantially free of rosuvastatin diol Ci- C 4 ester.
- rosuvastatin triol t-butyl ester substantially free of rosuvastatin diol t-butyl ester
- Rosuvastatin triol acid substantially free of rosuvastatin diol acid
- Rosuvastatin triol salt preferably calcium salt
- Rosuvastatin triol lactone substantially free of rosuvastatin diol lactone.
- the present invention also provides each of the above forms of the rosuvastatin triol in racemic, (7S) and (7R) configuration.
- the (7S) and (7R) configurations are diastereoisomers.
- the present invention provides: a) Rosuvastatin triol Ci-C 4 ester, preferably t-butyl ester, in racemic, (7S) and (7R) forms.
- the (7S) form is substantially free of the (7R) form.
- the (7R) form is substantially free of the (7S) form.
- the (7S) form is substantially free of the (7R) form.
- the (7R) form is substantially free of the (7S) form.
- Rosuvastatin triol salt such as calcium
- the (7S) form is substantially free of the (7R) form. In one embodiment the (7R) form is substantially free of the (7S) form. d) Rosuvastatin triol lactone in racemic, (7S) and (7R) forms. In one embodiment, the (7S) form is substantially free of the (7R) form, hi one embodiment, the (7R) form is substantially free of the (7S) form.
- the present invention also provides a method for preparing rosuvastatin triol ester.
- the triol ester can be prepared by oxidizing rosuvastatin Ci-C 4 ester, particularly t-butyl ester.
- the oxidation of the ester can be carried out by combining rosuvastatin Ci -C 4 ester, particularly t-butyl ester, with borane (e.g. BH 3 , B 2 H 6 ).
- borane e.g. BH 3 , B 2 H 6
- Complexes of borane, as well as various monoalkyl (Ci-Cg)- and dialkyl (Ci-C 8 )- boranes may be used.
- a solution of borane dimethylsulfide complex in a suitable organic solvent is combined with the ester.
- the reaction mixture can be stirred.
- a solution of an inorganic base, preferably NaOH, in water is then combined with the reaction mixture followed by addition of H 2 O 2 (preferably about 30% in water).
- the H 2 O 2 is preferably added dropwise.
- the temperature during H 2 O 2 addition is preferably kept below about 5O 0 C.
- oxidation reagents can be used.
- any other peroxides can be used including t-Butyl Hydroperoxide (TBHP) and Magnesium monoperoxyphthalate hexahydrate (MMPP).
- TBHP t-Butyl Hydroperoxide
- MMPP Magnesium monoperoxyphthalate hexahydrate
- the inorganic base is preferably an alkali metal base, more preferably a hydroxide base, such as NaOH, KOH and LiOH.
- a hydroxide base such as NaOH, KOH and LiOH.
- Another base that can be used is NH 4 OH.
- the organic phase can be separated and washed with water and/or brine to remove water miscible by-products such as borane by products (e.g.: H 3 BO 3 ). It can also be washed with sodium sulphite to remove excess hydrogen peroxide.
- the organic phase can then be concentrated to obtain a residue. Concentration can be done by reducing the pressure to less than 1 atmosphere such as less than about lOOmmHg.
- a precipitating agent such as ammonium chloride or another salt can be added to precipitate impurities out of the reaction mixture.
- Ammonium chloride is used to remove H 3 BO 3 , the reaction-by-product.
- an acid such as acetic acid or HCl can be used to neutralize the basic mixture.
- the H 3 BO 3 can be removed by washing with water.
- the rosuvastatin triol ester can then be purified and isolated from the corresponding rosuvastatin diol ester by chromatography.
- the present invention provides rosuvastatin triol ester in its isolated form.
- the triol ester can then be converted to the corresponding acid, salt or lactone.
- the triol ester can be converted to the triol salt by hydrolysis of the ester and addition of a suitable source of ions.
- a suitable source of ions e.g., sodium hydroxide and calcium chloride can be used, or calcium hydroxide can be used.
- the rosuvastatin ester can be converted to the salt by suspending the ester in a mixture of an organic solvent and water mixture and combined with a base such as sodium hydroxide to obtain a solution.
- the organic solvent may be Ci-C 4 alcohol, preferably ethanol.
- the organic solvent is then evaporated under reduced pressure followed by addition of calcium chloride, which results in precipitation of the calcium salt of the triol.
- the precipitate can be recovered by conventional techniques such as filtration.
- the present invention provides rosuvastatin triol salt in its isolated form.
- the salt is combined with an acid, such as hydrochloric or sulfuric acid.
- Rosuvastatin triol calcium is suspended in an organic solvent such as dichloromethane, to which aqueous HCl is added.
- the rosuvastatin triol acid is then isolated from the reaction mixture, such as by separation of the organic phase followed by removal of organic solvent, such as by evaporation under reduced pressure.
- the acid can also be obtained after hydrolysis of the ester, by acidification of the reaction mixture instead of addition of calcium chloride.
- Inorganic acids such as HCl and H 2 SO 4 can be used.
- the present invention provides rosuvastatin triol acid in its isolated form.
- the rosuvastatin lactone can then be obtained from the acid under conditions that favor lactonization.
- rosuvastatin triol calcium is dissolved in in an organic solvent such as acetonitrile, to which aqueous HCl is added.
- the reaction mixture can then be stirred.
- the organic solvent and water can then be removed, such as by evaporation under reduced pressure to obtain the lactone.
- rosuvastatin triol acid namely rosuvastatin triol acid, salt, lactone and ester
- Figure 2 illustrates that the compounds of the present invention can used as reference standards to both quantify and identify amount of impurities present in a composition of rosuvastatin.
- Rosuvastatin triol calcium is close to rosuvastatin diol calcium on the column, yet does not overlap with the peak for rosuvastatin. This lack of overlap is ideal since it can make quantification easier.
- the present invention provides rosuvastatin triol lactone in its isolated form.
- the present invention provides a process for reducing amount of rosuvastatin triol calcium present in a mixture comprising rosuvastatin calcium and rosuvastatin triol calcium comprising measuring amount of rosuvastatin calcium triol in batches of rosuvastatin diol calcium, selecting batches of the rosuvastatin diol with desirable level of the triol and preparing pharmaceutical compositions with the selected rosuvastatin diol batch. Salts in general other than calcium can also be used in this process.
- the present invention provides a process for reducing amount of rosuvastatin triol calcium present in a mixture comprising rosuvastatin diol calcium and rosuvastatin triol calcium comprising measuring amount of rosuvastatin triol Ci-C 4 ester in batches of rosuvastatin diol Ci-C 4 ester, selecting batches of the rosuvastatin diol C J -C 4 ester with of the triol Ci-C 4 ester and preparing pharmaceutical compositions of rosuvastatin diol calcium with the selected rosuvastatin diol Ci-C 4 ester batch.
- the ester is preferably t-butyl.
- the present invention provides a process for reducing amount of rosuvastatin triol calcium present in a mixture comprising rosuvastatin diol calcium and rosuvastatin triol calcium comprising measuring amount of rosuvastatin triol lactone in batches of rosuvastatin diol lactone, selecting batches of the rosuvastatin diol lactone with desirable level of the triol lactone and preparing pharmaceutical compositions of rosuvastatin diol calcium with the selected rosuvastatin diol lactone batch.
- the present invention provides a process for reducing amount of rosuvastatin triol calcium present in a mixture comprising rosuvastatin diol calcium and rosuvastatin triol calcium comprising measuring amount of rosuvastatin triol acid in batches of rosuvastatin diol acid, selecting batches of the rosuvastatin diol acid with desirable level of the triol acid and preparing pharmaceutical compositions of rosuvastatin diol calcium with the selected rosuvastatin diol acid batch.
- the present invention provides a method of determining the amount of an impurity in a sample of rosuvastatin diol ester (preferable t-butyl ester) comprising measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol ester in a reference standard comprising a known amount of rosuvastatin triol ester (preferably t-butyl); measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol ester in a test sample comprising rosuvastatin triol and rosuvastatin diol esters (preferably t-butyl); and determining the amount of the triol ester in the sample by comparing the area of reference standard with that of the test sample.
- the present invention provides a method of determining the amount of an impurity in a sample of rosuvastatin calcium comprising measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol calcium in a reference standard comprising a known amount of rosuvastatin triol calcium; measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol calcium in a test sample comprising rosuvastatin triol and rosuvastatin diol calcium salts; and determining the amount of the triol calcium in the sample by comparing the area of reference standard with that of the test sample. Salts in general other than calcium can also be used in this process.
- the present invention provides a method of determining the amount of an impurity in a sample of rosuvastatin acid comprising measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol acid in a reference standard comprising a known amount of rosuvastatin triol acid; measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol acid in a test sample comprising rosuvastatin acid and rosuvastatin diol acid; and determining the amount of the triol acid in the sample by comparing the area of reference standard with that of the test sample.
- the present invention provides a method of determining the amount of an impurity in a sample of rosuvastatin lactone comprising measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol lactone in a reference standard comprising a known amount of rosuvastatin triol lactone; measuring by GC or HPLC the area under a peak corresponding to rosuvastatin triol lactone in test a sample comprising rosuvastatin triol lactone and rosuvastatin diol lactone; and determining the amount of the triol lactone in the sample by comparing the area of reference standard with that of the test sample.
- the present invention provides a method of identifying the relative retention time (RRT) of an impurity in a sample of rosuvastatin diol ester (preferably t-butyl) comprising measuring by GC or HPLC the relative retention time (RRT) corresponding to rosuvastatin triol ester in a reference marker sample; carrying out GC or HPLC with a test sample comprising of the rosuvastatin ester and rosuvastatin triol ester to obtain an HPLC or GC chromatogram with retention times; and determining the relative retention time (RRT) of the triol ester in the sample by comparing the relative retention time (RRT) of the reference marker to the relative retention time (RRT) of the test sample.
- the rosuvastatin diol and rosuvastatin triol ester are tert-butyl esters.
- the present invention provides a method of determining the relative retention time (RRT) of an impurity in a sample of rosuvastatin diol calcium comprising measuring by GC or HPLC the relative retention time (RRT) corresponding to rosuvastatin triol calcium in a reference marker sample; carrying out GC or HPLC with a test sample comprising of the rosuvastatin diol and rosuvastatin triol calcium salts to obtain an HPLC chromatogram with retention times; and determining the relative retention time (RRT) of the triol calcium in the sample by comparing the relative retention time (RRT) of the reference marker to the relative retention time (RRT) of the test sample. Salts in general other than calcium can also be used in this process.
- the present invention provides a method of identifying the relative retention time (RRT) of an impurity in a sample of rosuvastatin diol acid comprising measuring by GC or HPLC the relative retention time (RRT) corresponding to rosuvastatin triol acid in a reference marker sample; carrying out GC or HPLC with a test sample comprising of the rosuvastatin diol acid and rosuvastatin triol acid to obtain an HPLC chromatogram with retention times; and determining the relative retention time (RRT) of the triol acid in the sample by comparing the relative retention time (RRT) of the reference marker to the relative retention time (RRT) of the test sample.
- RRT relative retention time
- the present invention provides a method of determining the relative retention time (RRT) of an impurity in a sample of rosuvastatin diol lactone comprising measuring by GC or HPLC the relative retention time (RRT) corresponding to rosuvastatin triol lactone in a reference marker sample; carrying out GC or HPLC with a test sample comprising of the rosuvastatin diol acid and rosuvastatin triol acid to obtain an HPLC chromatogram with retention times; and determining the relative retention time (RRT) of the triol acid in the sample by comparing the relative retention time (RRT) of the reference marker to the relative retention time (RRT) of the test sample.
- RRT relative retention time
- TBRE (10 g) was mixed with IM solution of borane dimethylsulfide complex in THF (56 ml) in an inert atmosphere. The mixture was stirred for 3 h at 2O 0 C. A solution of NaOH (74 g) in water (5 ml) was slowly added. H 2 O 2 (30% in water, 15 ml) was added dropwise, so that the temperature of the mixture was kept below 5O 0 C. The mixture was stirred for 0.5 h. A concentrated solution of ammonium chloride (150 ml) was added, and the precipitate was filtered out.
- Rosu triol Ca (0.5g) is suspended in dichloromethane (5 mL) and HCl (IN in water, 1 mL) is added. After stirring for 15 minutes phases are separated, and organic phase is concentrated in vacuum, giving the residue, which contains mainly the product. It may be additionally purified by column chromatography (silica gel, dichloromethane- methanol mixtures as eluent), giving pure Rosu triol acid.
- Rosu triol Ca (4 g) is dissolved in acetonitrile (40 mL) and HCl (IN in water, 40 mL) is added. The mixture is stirred at room temperature overnight. Acetonitrile and water are removed by distillation at reduced pressure. The residue, containing the product, may be additionally purified by flash chromatography (silica gel, hexane-ethyl acetate mixtures as eluent), giving pure rosu triol lactone.
- Nebulizer 60 psig
- V cap 4000 V
- RT of TBRE about 24.5min
- RRT of Triol -TBRE impurity is 0.6 corresponding to the main peak of TBRE.
- RRT of Triol -ROSU impurity is 0.7 corresponding to the main peak of ROSU.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0803085-5A BRPI0803085A2 (en) | 2007-03-13 | 2008-03-13 | rosuvastatin triol form |
CA2680604A CA2680604C (en) | 2007-03-13 | 2008-03-13 | Triol form of rosuvastatin |
EP08726880A EP2121631A2 (en) | 2007-03-13 | 2008-03-13 | Triol form of rosuvastatin |
JP2009504512A JP5330225B2 (en) | 2007-03-13 | 2008-03-13 | Triol rosuvastatin |
MX2008014552A MX2008014552A (en) | 2007-03-13 | 2008-03-13 | Triol form of rosuvastatin. |
IL200449A IL200449A0 (en) | 2007-03-13 | 2009-08-18 | Triol form of rosuvastatin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90691407P | 2007-03-13 | 2007-03-13 | |
US60/906,914 | 2007-03-13 | ||
US91846607P | 2007-03-15 | 2007-03-15 | |
US60/918,466 | 2007-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008112317A2 true WO2008112317A2 (en) | 2008-09-18 |
WO2008112317A3 WO2008112317A3 (en) | 2008-11-06 |
Family
ID=39650560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/003470 WO2008112317A2 (en) | 2007-03-13 | 2008-03-13 | Triol form of rosuvastatin |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2121631A2 (en) |
JP (1) | JP5330225B2 (en) |
KR (1) | KR100945760B1 (en) |
BR (1) | BRPI0803085A2 (en) |
CA (1) | CA2680604C (en) |
IL (1) | IL200449A0 (en) |
MX (1) | MX2008014552A (en) |
WO (1) | WO2008112317A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130066074A1 (en) * | 2010-06-07 | 2013-03-14 | Pharmathen S.A. | Process for the preparation of propenal intermediate and derivatives thereof |
CN112782333A (en) * | 2020-12-25 | 2021-05-11 | 石家庄四药有限公司 | HPLC detection method for pitavastatin isopropyl tert-butyl ester diastereoisomer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004032465D1 (en) * | 2003-12-02 | 2011-06-09 | Teva Pharma | REFERENCE STANDARD FOR THE CHARACTERIZATION OF ROSUVASTATIN |
-
2008
- 2008-03-13 JP JP2009504512A patent/JP5330225B2/en not_active Expired - Fee Related
- 2008-03-13 KR KR1020087027688A patent/KR100945760B1/en not_active IP Right Cessation
- 2008-03-13 MX MX2008014552A patent/MX2008014552A/en active IP Right Grant
- 2008-03-13 CA CA2680604A patent/CA2680604C/en not_active Expired - Fee Related
- 2008-03-13 WO PCT/US2008/003470 patent/WO2008112317A2/en active Application Filing
- 2008-03-13 EP EP08726880A patent/EP2121631A2/en not_active Withdrawn
- 2008-03-13 BR BRPI0803085-5A patent/BRPI0803085A2/en not_active IP Right Cessation
-
2009
- 2009-08-18 IL IL200449A patent/IL200449A0/en unknown
Non-Patent Citations (1)
Title |
---|
STROBEL, H.A.; HEINEMAN, W.R.: "Chemical Instrumentation: A Systematic Approach", 1989, WILEY & SONS |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130066074A1 (en) * | 2010-06-07 | 2013-03-14 | Pharmathen S.A. | Process for the preparation of propenal intermediate and derivatives thereof |
US8575343B2 (en) * | 2010-06-07 | 2013-11-05 | Pharmathen S.A. | Process for the preparation of a propenal intermediate and derivatives thereof |
CN112782333A (en) * | 2020-12-25 | 2021-05-11 | 石家庄四药有限公司 | HPLC detection method for pitavastatin isopropyl tert-butyl ester diastereoisomer |
Also Published As
Publication number | Publication date |
---|---|
MX2008014552A (en) | 2009-03-09 |
JP5330225B2 (en) | 2013-10-30 |
KR20090010195A (en) | 2009-01-29 |
IL200449A0 (en) | 2010-04-29 |
BRPI0803085A2 (en) | 2011-08-30 |
EP2121631A2 (en) | 2009-11-25 |
JP2009519353A (en) | 2009-05-14 |
WO2008112317A3 (en) | 2008-11-06 |
CA2680604C (en) | 2012-08-07 |
KR100945760B1 (en) | 2010-03-08 |
CA2680604A1 (en) | 2008-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7741482B2 (en) | Reference standard for characterization of rosuvastatin | |
US7566782B2 (en) | Process for the preparation of rosuvastatin | |
US20070037979A1 (en) | Preparation of rosuvastatin | |
JPH0641448B2 (en) | 3-demethylmevalonic acid derivative | |
JP2002515498A (en) | 5-Demethoxyfumadirole derivative and method for producing the same | |
CA2680604C (en) | Triol form of rosuvastatin | |
US7851624B2 (en) | Triol form of rosuvastatin and synthesis of rosuvastatin | |
US7884226B2 (en) | Purification of rosuvatatin intermediate by thin film evaporation and chemical method | |
US20110245285A1 (en) | Process for preparation of rosuvastatin acetonide calcium | |
Schneider et al. | Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection | |
CN101631777A (en) | Triol form of rosuvastatin | |
JPS6251639A (en) | 6-phenoxymethyl-4-hydroxytetrahydropyrane-2-ones and manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880008162.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009504512 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008726880 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08726880 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2008/014552 Country of ref document: MX Ref document number: 1020087027688 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4791/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200449 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2680604 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: PI0803085 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081112 |